GLP-1 medications, widely recognized for their efficacy in weight loss and diabetes management, are increasingly linked to hair thinning and loss, a concern now substantiated by new research. These appetite-suppressing drugs, including brand names like Ozempic and Wegovy, mimic a gut hormone to regulate appetite and blood sugar, revolutionizing obesity treatment. While their metabolic and cardiovascular benefits are well-established, a growing number of users have reported distressing hair loss, with some experiencing bald patches.

The US Food and Drug Administration (FDA) initiated an investigation into the potential link between GLP-1 jabs and alopecia in January 2024. Although earlier research suggested hair loss affected less than 5% of users for the majority of these drugs, a recent US study has provided clearer evidence. Presented at the European Academy of Dermatology and Venereology 2025 Congress, the research links GLP-1s to rapid hair loss, medically termed telogen effluvium (TE), as well as male and female pattern baldness, and nonscarring hair loss. Notably, no association was found with alopecia areata, an autoimmune disease affecting hair follicles.

The retrospective study, conducted by researchers from the George Washington University School of Medicine and Health Sciences, analyzed over 1 million patients without a history of hair loss or predisposing conditions like thyroid disease. After adjusting for confounding factors such as age, sex, race, and BMI, the study identified 547,993 GLP-1 users who had received at least two prescriptions between 2014 and 2024. These users were matched with an equal number of non-users. Over the 10-year period, the incidence of rapid hair loss, pattern baldness, and nonscarring hair loss significantly increased in patients using weight loss jabs compared to non-users.

Specific findings from the study reveal a substantial increase in risk: after just six months of GLP-1 jab use, the risk of nonscarring hair loss increased by 26%, and the risk of pattern baldness rose by 62%. After one year, the risk of developing rapid hair loss was highest, at 76% higher with weight loss drug use. Senior author Yagiz Matthew Akiska highlighted that hair loss can be particularly debilitating for patients who are already concerned about their appearance while trying to lose weight or manage diabetes.

While GLP-1 drugs target receptors related to digestion and insulin production, not directly hair growth, experts suggest that the stress on the body caused by rapid weight loss can disrupt the hair's natural cycle. Dr. Roshan Vara, a hair transplant surgeon, explained that dramatic changes in nutrient intake can lead to deficiencies in essential nutrients required for hair growth. Calorie restriction, often unintended with products like Mounjaro or Wegovy, can cause the body to prioritize essential functions, diverting nutrients away from hair and towards internal organs.

The good news is that this type of hair loss is often reversible, with hair typically regrowing within six months once nutrient intake is restored. Given these findings, experts like Dr. Akiska advocate for proactive strategies to mitigate these risks. Doctors advise patients on weight loss jabs to carefully monitor their diet, ensuring nutrient density even with reduced appetite, and to consult a medical professional if hair loss persists despite managing stress and maintaining a healthy diet. Mr. Michael Buontempo, a resident physician not involved in the study, reinforced that pacing weight loss and maintaining nutrition are the best mitigation strategies, suggesting that hair loss is a side effect of rapid weight loss rather than the drug itself. Doctors are encouraged to counsel eligible patients about this emerging real-world side effect.